COVID-19 Therapeutic Alert - Palivizumab passive immunisation against respiratory syncytial virus (RSV) in at risk pre-term infants

Updated UK rapid policy statement extends eligibility for palivizumab beyond JCVI guidance, specifically in context of COVID-19 pandemic, in light of atypical current seasonal pattern of infection, and increases the maximum number of doses from five to seven.

Source:

Department of Health and Social Care